Ascent Pediatrics expands
Ascent Pediatrics announced that it plans to expand its field sales force.
One year after Ascent Pediatrics was formed to develop and promote pharmaceutical products exclusively to children, the Wilmington, DE-based firm announced that it plans to expand its field sales force.
In response to a recently announced agreement with Warner-Lambert Co., Ascent will expand its sales force by 34% in order to copromote the cephalosporin antibiotic Omnicef® to pediatricians.
"This increase in sales personnel will enable Ascent to seek additional opportunities for introducing significant new pharmaceutical products to the pediatric market," said Alan Fox, president and CEO of Ascent.
In 1997, the pediatric market for pharmaceutical products was estimated to be worth approximately $4 billion.
Currently, Ascent promotes Feverall® Acetaminophen Suppositories and Pediamist® Nasal Mist. In the second half of 1999, Ascent said it expects to begin marketing two new markets, pending FDA approval. The products are Primsol® Solution, an antibiotic for acute otitis media, and Oraped,® an improved tasting formulation of liquid prednisolone.
When Ascent first entered the market, it reported employing a sales force of 65 sales reps. PR
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Applying Porter’s Five Forces to Portfolio Management in Pharmaceutical R&D: A Strategic Roadmap
March 17th 2025The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.
